Skip to Main Content

Paper Details

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.
J Immunother Cancer
16
2021
Cancer, cancer, cytotoxic T-lymphocyte-associated protein 4, immune, immune cell subsets, irAE, irAEs, patient, programmed death protein 1, programmed-death ligand 1
Author NameAffiliation
Elizabeth M JaffeeJohns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center
William J MurphyInstitute for Regenerative Cures, University of California Davis
Alexandra-Chloé VillaniCenter for Cancer Research, Center for Immunology and Inflammatory Diseases, Harvard Medical School, Massachusetts General Hospital
Alexandra-Chloé VillaniBroad Institute
Theresa L WalunasDepartment of Medicine and Center for Health Information Partnerships, Northwestern University Feinberg School of Medicine
  • 1 - 5

Datasets

Release 1.2